A pharmacophore‐based classification better predicts the outcomes of HER2‐negative breast cancer patients receiving the anthracycline‐ and/or taxane‐based neoadjuvant chemotherapy

AIMS: Prognosis of patients for human epidermal growth factor receptor 2 (HER2)‐negative breast cancer post neoadjuvant chemotherapy is not well understood. The aim of this study was to develop a novel pharmacophore‐based signature to better classify and predict the risk of HER2‐negative patients af...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xuan, Sun, Hefen, Liu, Qiqi, Liu, Yang, Hou, Yifeng, Jin, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Bioinformatics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267145/
https://www.ncbi.nlm.nih.gov/pubmed/34076352
http://dx.doi.org/10.1002/cam4.4022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267145/
https://www.ncbi.nlm.nih.gov/pubmed/34076352
http://dx.doi.org/10.1002/cam4.4022

Ejemplares similares